These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31158244)

  • 21. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
    Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
    Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
    Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
    Johnson DB; Childress MA; Chalmers ZR; Frampton GM; Ali SM; Rubinstein SM; Fabrizio D; Ross JS; Balasubramanian S; Miller VA; Stephens PJ; Sosman JA; Lovly CM
    Pigment Cell Melanoma Res; 2018 May; 31(3):432-436. PubMed ID: 29171936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 27. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
    J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
    Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
    Suzuki R; Kikuchi S; Harada T; Mimura N; Minami J; Ohguchi H; Yoshida Y; Sagawa M; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi N; Ando K; Utsugi T; Hideshima T; Anderson KC
    PLoS One; 2015; 10(12):e0143847. PubMed ID: 26630652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
    Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N
    Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury.
    Li JX; Feng JM; Wang Y; Li XH; Chen XX; Su Y; Shen YY; Chen Y; Xiong B; Yang CH; Ding J; Miao ZH
    Cell Death Dis; 2014 Jun; 5(6):e1278. PubMed ID: 24901049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
    Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.